Clinical Research: Available Trials

Picture
CMOH offers clinical trials through US Oncology Research, one of the largest community-based research programs in the U.S., with over 60 research sites. US Oncology Research has enrolled over 80,000 patients in clinical trials and played a role in nearly 100 FDA-approved cancer therapies.
Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. CMOH's physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with The US Oncology Network.  You do not have to leave the area to receive premier cancer care.

 If you are interested in learning more about our research program, please contact (215) 658-7240. 

CMOH OPEN TRIALS AS OF April 12, 2021:
CONTACT BECKI BANAS FOR PATIENT SCREENING OR ANY ADDITIONAL TRIAL INFORMATION
BECKI.BANAS1@USONCOLOGY.COM
215-370-6701

ANAL
USOR  20189:  Incyte:  INCMGA00012vs Placebo with Paclitaxel/Carboplatin for Metastatic SCC AnalNCT04472429

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249            
____________________________________________
BILIARY
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
BLADDER
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
BONE METS
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
BRAIN CANCER
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
BREAST
USOR 17079:  Agendia: FLEX STUDY-MammaPrint Blueprint-Data Trial:                                  NCT03053193

USOR 14059: Pharmacyclics: IBRUTINIB and HERCEPTIN for HER2 amplified                          NCT03379428

USOR 20431: PRESERVE2: Gi Therapeutics: TRILACICLIB vs Placebo with GEM/CARBO TRIPLE NEG     NCT04799249
​
USOR 20417: Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer NCT03742102

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
CARCINOID
USOR  20189:  Incyte:  INCMGA00012vs Placebo with Paclitaxel/Carboplatin for Squamous CellAnalNCT04472429                                     
____________________________________________
CERVICAL
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
COLON
USOR 20318:  Mirati:  MRTX849 with Cetuximab vs Folfox/Folfiri for KRASG12C mutationNCT04793958

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
ENDOMETRIAL
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
ESOPHAGEAL
USOR 20171: ORIENT-15:Covance: Sintilimab vs Plac w Cis/PaclitaxelorCis/5FU for SCC     NCT03748134

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249

ESSENTIAL THROMBOCYTHEMIA
USOR 19171: CTI BioPharma: Pacritinib vs Phys Ch for Myelofib, PV=Myelofib,PEMyelofibNCT03165734
____________________________________________
FALLOPIAN
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
GALL BLADDER
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
GASTRIC
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
HEAD AND NECK
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
KAPOSIS SARCOMA
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
KIDNEY
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
LEUKEMIA
USOR 20282: CABL001AUS04: Novartis: Asciminib in Chronic Phase  +/- T315  mutation     NCT04666259

USOR 18263: BeiGene: Zanubrutinib in Patients with CLL intolerant to Acalabrutinib          NCT03206918
____________________________________________
LIVER
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
LUNG
USOR 19239: KEAPSAKE: Calithera: Telaglenastat vs Placebo with Pembro + Chemo wKEAP1NRF2mutNCT04265534

USOR 20249: Janssen: Amivantamab vs Placebo with Carbo and Pemetrexed with EGFR EXON20ins       NCT04538664

USOR 20250:MARIPOSA: Janssen: Amivantamab+Lazertinib or Osimertinib vs Lazertinib EGFR  NCT04487080

USOR 20412:LIBRETTO-432:Lilly:Selpercatinib f/b Definitive Locoregional tx for IB-IIIRET+NCT04819100        

USOR 20331: Verastem: VS-6766(RAF/MEK inhib) as SA or in Combo with Defactinib(FAK inhib) in KRAS-MT          NCT04620330

USOR 19018: SAPPHIRE:Mirati: Sitravatinib and Nivolumab vs Docetaxel prev tx Platinum+CHEK Inhib NCT03906071

USOR 18164: Blueprint Medicine: BLU-667 for RET mutation                                                     NCT03037385

USOR 20270: MRTX849 in Combination with Pembrolizumab in Patients with Advanced NSCLCA with KRAS G12C NCT04613596 

USOR 20139: Neo ADAURA-Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with EGFR Resectable NSCLCA   NCT04351555
____________________________________________
LYMPHOMA-HODGKINS
USOR 11282: Seattle Genetics: Brentuximab Vedotin for pt ineligible for standard chemo NCT01716806

USOR 18013: Seattle Genetics: Brentuximab Vedotin in Classical Hodgkin Lymphoma        NCT03646123
____________________________________________
LYMPHOMA- NON HODGKINS
USOR 11282: Seattle Genetics: Brentuximab Vedotin for pt ineligible for standard chemo with  PTCL   NCT01716806

USOR 18263: BeiGene:Zanubrutinib in Patients with SLL, WM intolerant to Acalabrutinib  NCT03206918
____________________________________________
MALIGNANT ADENOCARCINOMA
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
MELANOMA-MERKEL CELL
USOR 17144: Exicure: Cavrotolimod with Pembrolizumab or Cemiplimab                              NCT03684785
____________________________________________
MYELODYSPLASTIC SYNDROME
USOR 20438:STIMULUS-MDS-US:Novartis: Sabatolimab vs Plac with Investigator Choice  NCT03946670
____________________________________________
MYELOFIBROSIS
USOR 19171: CTI Biopharma: Pacritinib Vs MD choice MF, PV-MF, PET-MF                            NCT03165734

USOR 20177: TRANSFORM-1: Abbvie: Navitoclax with Ruxolitinib vs Ruxolitinib alone       NCT04472598

USOR 20346: XPORT-MF-035 SELINEXOR VERSUS TREATMENT OF PHYSICIANíS CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS NCT04562870
____________________________________________
OVARIAN
USOR 20298: Verastem: VS-6766(RAF/MEK inhib) as SA or in Combo with Defactinib(FAK inhib) NCT04625270

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
PANCREATIC
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
PENILE
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
PERITONEAL
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
PROSTATE
USOR 19144: Janssen: Biomarker (Blood test-Invitae) study to Determine DNA-Repair Defects   NCT03871816

USOR 16238: TRITON 3: Clovis: Ruaparib vs Physicians Choice for pt with BRCA ½ or ATM NCT02975934

USOR 20248:Janssen:Niraparib vs Plac with Abiraterone Acetate+Predisone for patients with HRR or Germline MutNCT04497844

USOR 20138:CAPITELLO-281:AstraZeneca:Capivas ertib+AbirateronevsPlac+Abiraterone for mHSPC w PTEN NCT04493853
____________________________________________
RECTAL
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
SARCOMA
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
SOLID TUMOR
USOR 17144: Exicure: Cavrotolimod with Pembrolizumab or Cemiplimab                              NCT03684785

USOR 18164: Blueprint Medicine: BLU-667 for RET mutation                                                     NCT03037385

USOR 19092: Janssen: Erdafitinib for FGFR Gene Alterations                                                      NCT04083976

USOR 20186: TAPISTRY: Roche: Tumor agnostic Precision Immuno oncology and somatic targeting      NCT04589845

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
TESTICULAR
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
THYROID
USOR 18164: Blueprint Medicine: BLU-667 for RET mutation                                                     NCT03037385
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
UROTHELIAL
USOR 19032: Jannsen: Biomarker Study to Identify FGFR in Urothelial Cancer                      NCT03955913

USOR 20172:EVO-103: Seattle Genetics:Enfortumab Vedotin in combo w anticancer Adv+Mets NCT03288545                                

USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
UTERINE
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________
VAGINAL
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
____________________________________________​
VULVAR
USOR 19151: Roche: MRTX849 For Solid Tumors with KRASG12C                                             NCT03785249
cmoh_clinical_research_trials.pdf (uploaded 2021-10-12)
File Size: 374 kb
File Type: pdf
Download File

Learn more.

Take action.

"At CMOH, we are able to combine a personal touch with high quality treatment. This is a friendly environment. Our physicians, nurses and staff are all very approachable."  
- Maureen Lowry, MHA, BSN, RN, OCN